Endocrinology Research and Practice
Original Article

Increased Serum Nesfatin-1 Levels in Patients with Impaired Glucose Tolerance


Hacettepe University Faculty of Medicine, Department of Endocrinology and Metabolism Ankara, Turkey


Health Sciences University, Gülhane Faculty of Medicine, Department of Endocrinology and Metabolism, Ankara, TURKEY


Acıbadem University, Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey


Hacettepe University, Faculty of Medicine, Department of Biostatistics, Ankara, Turkey

Endocrinol Res Pract 2017; 21: 65-67
DOI: 10.25179/tjem.2017-56543
Read: 1086 Downloads: 304 Published: 01 September 2017


Purpose: Nesfatin-1 is a recently discovered energy-regulating peptide, widely expressed in both central and peripheral tissues. It is involved in various functions, such as the stimulation of hypothalamic-pituitary-adrenal axis and sympathetic nervous system, infl uencing visceral functions, water intake, and regulation of temperature and emotions. It exerts a direct glucose-dependent insulinotropic action on the beta cells of pancreatic islets. The current study evaluated nesfatin-1 levels and insulin response to glucose load in patients with impaired glucose tolerance (IGT) and in healthy subjects.

Material and Method: Of those patients who underwent the oral glucose tolerance test (OGTT), 14 with IGT and 13 body mass index- (BMI) and age-matched healthy subjects as controls were included in the study. Blood samples were taken at 0, 60 and 120 min, and the glucose, insulin, and nesfatin-1 levels were measured.

Results: The basal levels of glucose, insulin, and nesfatin–1 were significantly higher in the patients with IGT than in controls. Two-way repeated measures ANOVA revealed that change in time (CIT) for glucose and insulin during an OGTT was significant (p<0.001 and p<0.001, respectively). CIT for glucose and insulin was significantly different between the IGT patients and the controls (p<0.001 and p=0.003, respectively). CIT for nesfatin-1 was not significant (p=0.406) and did not differ significantly between the two groups (p=0.331).

Discussion: The elevated levels of basal nesfatin-1 were observed in the patients with IGT. There was no change in the absolute nesfatin– 1 levels in response to glucose load in either group. The increase in the levels of basal nesfatin-1 may refl ect a compensatory mechanism to regulate the impaired glucose metabolism in the IGT patients, which is later underwhelmed with the onset of diabetes.



EISSN 2822-6135